Gujarat Themis Biosyn’s ₹1,300 Cr MBJ deal to close Q2 FY27

Deal announcement and why it matters

Gujarat Themis Biosyn Limited (GTBL) has signed a definitive agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. (MBJ) for JPY 21.5 billion, which the company has indicated is about ₹1,300 crore. GTBL described the transaction as its largest acquisition to date and a strategic step toward becoming a globally integrated CDMO. The acquisition is intended to expand GTBL’s capabilities beyond its existing fermentation-based API business and improve access to international markets. The purchase is being positioned as a pivot from a largely domestic API manufacturing base toward microbial fermentation and biopharmaceutical capabilities.

Transaction structure, buyer, and seller

The acquisition will be executed through Themis Biosyn Japan Limited, a wholly owned subsidiary incorporated in Japan. GTBL is acquiring MBJ from funds managed or advised by T Capital Partners Co., Ltd. The company has disclosed that the transaction is not a related party transaction. GTBL also stated that MBJ’s existing management team is expected to continue leading operations after the acquisition, indicating operational continuity.

Consideration and funding plan

The consideration is approximately JPY 21.5 billion (about ₹1,300 crore), payable at closing. GTBL has said the transaction is expected to be funded through an optimal mix of debt and equity. The company has also communicated that the deal is expected to be EPS accretive. Beyond these points, no additional financial terms were provided in the disclosed details.

Regulatory approvals and expected timeline

Completion is subject to approvals under Japan’s Foreign Exchange and Foreign Trade Act (FEFTA), along with other applicable regulatory approvals and customary closing conditions. GTBL expects the transaction to close in Q2 FY2027. The disclosure was signed by Dinesh S. Patel, Chairman and Director of Gujarat Themis Biosyn Limited, on May 22, 2026.

New Japan subsidiary created for the acquisition

Ahead of the transaction, GTBL incorporated Themis Biosyn Japan Limited on May 19, 2026. The subsidiary has a share capital of ten lakhs yen and is fully owned by GTBL (100% shareholding). As it is newly incorporated, turnover was stated as not applicable. The company also said that no specific regulatory approvals were required for the incorporation and that it was completed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

What MBJ brings: approvals and capability mix

GTBL’s materials highlight MBJ’s presence in precision fermentation and biologics capabilities. MBJ is also described as having FDA and PMDA approvals, and as operating in areas that include fermentation, plasmid DNA, and ADC conjugation. GTBL has additionally indicated that around 40% of MBJ’s revenue comes from outside Japan and that MBJ serves top global pharma firms. The stated intent is to use these capabilities to accelerate GTBL’s entry into biologics and newer modalities.

GTBL’s current business context

GTBL is principally engaged in manufacturing pharmaceuticals and medicinal chemical products, with a focus on fermentation-based APIs. Its portfolio includes Rifamycin-S and Lovastatin, and the company exports to Europe and the United States. A separate company profile note in the provided information states GTBL has two major customers accounting for 90% to 95% of its sales, and that it is planning capital expenditures of ₹200 crore to expand capacity, develop new products, and enter new markets. The acquisition is being framed as a step that complements GTBL’s fermentation background while widening its end markets.

Market snapshot: stock move and valuation references

On the day referenced in the provided market snapshot, Gujarat Themis Biosyn’s share price was reported down 4.74% from the previous close of ₹424.30, last trading at ₹404.20. The company was also described as a small-cap stock with a market capitalisation of ₹4,404.38 crore. The article context noted the deal’s magnitude of about ₹1,300 crore as comparable to GTBL’s market capitalisation from two years ago, emphasising the scale of capital deployment relative to the company’s size.

Key facts at a glance

Why investors are watching the deal size and integration focus

The acquisition size is material for GTBL, given the reported market capitalisation of ₹4,404.38 crore and the transaction value of about ₹1,300 crore. GTBL has also communicated that the acquisition is expected to be EPS accretive, which makes subsequent disclosures on integration, financing mix, and operational performance important for investors tracking execution. At the same time, the company’s stated goal of moving toward a globally integrated CDMO model suggests a broader shift in business mix, including increased exposure to international customers and regulated markets.

Conclusion

GTBL’s definitive agreement to acquire MBJ for JPY 21.5 billion (about ₹1,300 crore) is structured through its newly incorporated Japan subsidiary and is expected to close in Q2 FY2027, subject to FEFTA and other regulatory approvals. The next key milestones are regulatory clearances and completion of closing conditions, after which the company will be expected to outline how it plans to integrate MBJ’s capabilities into its wider fermentation and biopharma roadmap.